A detailed history of Macquarie Group LTD transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 4,272,914 shares of TVTX stock, worth $79.3 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
4,272,914
Previous 4,367,830 2.17%
Holding current value
$79.3 Million
Previous $35.9 Million 66.5%
% of portfolio
0.07%
Previous 0.04%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.89 - $15.21 $748,887 - $1.44 Million
-94,916 Reduced 2.17%
4,272,914 $59.8 Million
Q2 2024

Aug 09, 2024

SELL
$5.26 - $8.28 $1.29 Million - $2.03 Million
-245,229 Reduced 5.32%
4,367,830 $35.9 Million
Q1 2024

May 14, 2024

SELL
$7.18 - $9.82 $960,088 - $1.31 Million
-133,717 Reduced 2.82%
4,613,059 $35.6 Million
Q4 2023

Feb 14, 2024

BUY
$5.44 - $9.5 $407,548 - $711,711
74,917 Added 1.6%
4,746,776 $42.7 Million
Q3 2023

Nov 14, 2023

BUY
$7.64 - $17.25 $5.49 Million - $12.4 Million
718,745 Added 18.18%
4,671,859 $41.8 Million
Q2 2023

Aug 14, 2023

BUY
$15.3 - $22.61 $4.72 Million - $6.97 Million
308,427 Added 8.46%
3,953,114 $60.7 Million
Q1 2023

May 15, 2023

BUY
$17.82 - $22.89 $1.58 Million - $2.03 Million
88,575 Added 2.49%
3,644,687 $82 Million
Q4 2022

Feb 21, 2023

BUY
$18.47 - $26.14 $4.54 Million - $6.43 Million
245,856 Added 7.43%
3,556,112 $74.8 Million
Q3 2022

Nov 14, 2022

SELL
$22.91 - $28.63 $8.21 Million - $10.3 Million
-358,423 Reduced 9.77%
3,310,256 $81.6 Million
Q2 2022

Aug 15, 2022

BUY
$20.94 - $30.01 $1.17 Million - $1.67 Million
55,778 Added 1.54%
3,668,679 $88.9 Million
Q1 2022

May 16, 2022

SELL
$23.61 - $30.6 $3.66 Million - $4.74 Million
-154,991 Reduced 4.11%
3,612,901 $93.1 Million
Q4 2021

Feb 11, 2022

SELL
$24.34 - $31.17 $4.48 Million - $5.73 Million
-183,949 Reduced 4.65%
3,767,892 $117 Million
Q3 2021

Nov 12, 2021

BUY
$12.98 - $25.03 $511,775 - $986,882
39,428 Added 1.01%
3,951,841 $95.8 Million
Q2 2021

Aug 13, 2021

BUY
$14.11 - $26.4 $16.6 Million - $31 Million
1,174,860 Added 42.92%
3,912,413 $57.1 Million
Q1 2021

May 14, 2021

SELL
$23.37 - $31.77 $616,243 - $837,743
-26,369 Reduced 0.95%
2,737,553 $68.4 Million
Q4 2020

Feb 16, 2021

BUY
$19.17 - $27.87 $53 Million - $77 Million
2,763,922 New
2,763,922 $75.3 Million

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.19B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.